Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · Real-Time Price · USD
14.33
-0.14 (-0.93%)
Oct 8, 2025, 2:55 PM EDT - Market open
-0.93%
Market Cap45.02B
Revenue (ttm)31.05B
Net Income (ttm)949.04M
Shares Out 1.56B
EPS (ttm)0.59
PE Ratio24.22
Forward PE25.13
Dividend$0.54 (3.79%)
Ex-Dividend DateMar 31, 2025
Volume1,904,034
Open14.35
Previous Close14.46
Day's Range14.31 - 14.37
52-Week Range12.80 - 15.69
Beta0.26
Analystsn/a
Price Targetn/a
Earnings DateOct 30, 2025

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Sector Healthcare
Founded 1781
Employees 47,455
Stock Exchange NYSE
Ticker Symbol TAK
Full Company Profile

Financial Performance

In 2024, Takeda Pharmaceutical's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements

News

Takeda Pharmaceutical to exit cell therapy research

Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a partner to advance candidates under development.

7 days ago - Reuters

Bristol Myers, Takeda to pool data for AI-based drug discovery

Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and develop...

Other symbols: BMY
7 days ago - Reuters

Shares of Asian drugmakers drop after Trump threatens tariffs

Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...

12 days ago - Reuters

Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually

Takeda (TAK) offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class candidates, but ...

13 days ago - Seeking Alpha

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) part...

14 days ago - Business Wire

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical compan...

22 days ago - Business Wire

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, eff...

27 days ago - Business Wire

Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Milano Furuta - CFO & Director Conference C...

4 weeks ago - Seeking Alpha

Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)

Takeda Pharmaceutical Company Limited (NYSE:TAK) Oveporexton (TAK-861) Investor Call on Phase 3 Narcolepsy Type 1 Data Presented at World Sleep 2025 Company Participants Christopher David O'Reilly - ...

4 weeks ago - Seeking Alpha

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a...

4 weeks ago - Business Wire

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applicatio...

4 weeks ago - Business Wire

What's Going On With Takeda Stock On Friday?

On Friday, Takeda Pharmaceutical Co Ltd's TAK stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.

6 weeks ago - Benzinga

Japan's Takeda weighs India for global trials to speed up drug launches

Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting global clinical trials in India to accelerate the launch of its innovative drugs in the world's most populous nation, its...

6 weeks ago - Reuters

Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its m...

2 months ago - Newsfile Corp

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

2 months ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

2 months ago - CNBC Television

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited TAK posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a...

2 months ago - Benzinga

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q1 FY2025 Earnings Call July 30, 2025 6:00 AM ET Company Participants Furuta - Corporate Participant O'Reilly - Corporate Participant Plump - Corporat...

2 months ago - Seeking Alpha

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVAN...

2 months ago - Business Wire

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, ...

2 months ago - Business Wire

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

In my followup on Takeda Pharmaceutical Co (TAK), I am reaffirming my buy rating from March. Clinical demand in multiple areas, along with an active drug pipeline, could keep driving the top-line desp...

2 months ago - Seeking Alpha

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controll...

3 months ago - Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusio...

3 months ago - Business Wire

Takeda Announces New Assignments of Directors

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meet...

3 months ago - Business Wire

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, c...

4 months ago - Business Wire